Mainz Biomed (NASDAQ:MYNZ) Trading Up 12.4% – What’s Next?
by Sarita Garza · The Markets DailyMainz Biomed NV (NASDAQ:MYNZ – Get Free Report)’s stock price rose 12.4% during mid-day trading on Monday . The stock traded as high as $1.92 and last traded at $1.63. Approximately 65,779,351 shares changed hands during mid-day trading, an increase of 17,602% from the average daily volume of 371,589 shares. The stock had previously closed at $1.45.
Analysts Set New Price Targets
Separately, Maxim Group lowered shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.
Read Our Latest Analysis on MYNZ
Mainz Biomed Stock Up 12.4%
The company has a quick ratio of 0.43, a current ratio of 0.52 and a debt-to-equity ratio of 0.44. The firm has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $1.18. The company has a market capitalization of $14.77 million, a price-to-earnings ratio of -0.02 and a beta of 0.31.
Institutional Investors Weigh In On Mainz Biomed
Hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC raised its position in shares of Mainz Biomed by 45.0% in the 2nd quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after purchasing an additional 88,400 shares in the last quarter. Cerity Partners LLC acquired a new stake in shares of Mainz Biomed during the fourth quarter worth approximately $183,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Mainz Biomed by 200.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after buying an additional 20,000 shares during the last quarter.
Mainz Biomed Company Profile
Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.
The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.